ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Metrics to compare | 196170 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship196170PeersSector | |
|---|---|---|---|---|
P/E Ratio | 161.9x | −3.3x | −0.4x | |
PEG Ratio | 0.04 | −0.13 | 0.00 | |
Price/Book | 54.6x | 2.4x | 2.6x | |
Price / LTM Sales | 100.8x | 8.7x | 3.1x | |
Upside (Analyst Target) | 20.7% | 14.9% | 58.6% | |
Fair Value Upside | Unlock | 4.5% | 8.2% | Unlock |